Back to results
US 2020/0054737 A1Published application
Herpes simplex virus vaccine
AssigneeModema TX, Inc.
InventorsGiuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
Life of this patent
Estimating the term…
Abstract
The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims90
A herpes simplex virus (HSV) vaccine, comprising:
- at least one ribonucleic acid (RNA) polynucleotide having an open reading frame (ORF) encoding at least one HSV antigenic polypeptide,
- wherein the at least one RNA polypeptide is encoded by the ORF sequences of any one of SEQ ID NO:
- 128-131 and 141-144 and/or wherein the at least one RNA polynucleotide comprises the ORF sequence of any one of SEQ ID NO:
- 132-135 and 145-148.
1 more element
A herpes simplex virus (HSV) vaccine comprising:
- at least one ribonucleic acid (RNA) polynucleotide encoding at least one antigenic polypeptide, wherein the at least one antigenic polypeptide comprises (i) an amino acid sequence identified by any one of SEQ ID NO:
- 136-140;
- or (ii) an amino acid sequence that has at least 95% identity to an amino acid sequence identified by any one of SEQ ID NO:
- 136-140.
1 more element
A herpes simplex virus (HSV) comprising:
- (i) a RNA polynucleotide having an open reading frame encoding antigenic HSV glycoprotein D and (ii) a RNA polynucleotide having an open reading frame encoding an antigenic HSV glycoprotein B.
A herpes simplex virus (HSV) vaccine, comprising at least one messenger ribonucleic acid (mRNA) polynucleotide having a 5′ terminal cap, an open reading frame (ORF) encoding at least one HSV antigenic polypeptide, and a 3′ poly A tail, wherein the at least one mRNA polynucleotide is encoded by the ORF sequences of any one of SEQ ID NO:
- 128-131 and 141-144.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 132, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 132 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 133, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 133 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an ORF sequence of SEQ ID NO:
- 134, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 134 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 135, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 135 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 145, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 145 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 146, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 146 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 147, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 147 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A HSV vaccine, comprising:
- at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame (ORF) sequence of SEQ ID NO:
- 148, having a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, wherein the uracil nucleotides of the ORF sequence of SEQ ID NO:
- 148 are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A herpes simplex virus (HSV) vaccine, comprising
- at least two messenger ribonucleic acid (mRNA) polynucleotides, each encoding at least one antigenic HSV polypeptide, wherein a first mRNA polynucleotide encodes at least an HSV-2 glycoprotein B and a second mRNA polynucleotide encodes at least an HSV-2 glycoprotein D, wherein each mRNA has a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, and wherein the uracil nucleotides of the mRNA are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A herpes simplex virus (HSV) vaccine, comprising
- at least three messenger ribonucleic acid (mRRNA) polynucleotides encoding at least three antigenic HSV polypeptides, wherein a first nmRNA polynucleotide encodes a HSV-2 glycoprotein B, a second mRNA polynucleotide encodes a HSV-2 glycoprotein D, and a third mRNA encodes a HSV-2 glycoprotein C, wherein each mRNA has a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, and wherein the uracil nucleotides of the mRNA are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A herpes simplex virus (HSV) vaccine, comprising
- at least four messenger ribonucleic acid (mRNA) polynucleotides encoding an antigenic HSV polypeptide, wherein a first mRNA polynucleotide encodes a HSV-2 glycoprotein B, a second mRNA polynucleotide encodes a HSV-2 glycoprotein D antigenic, a third mRNA encodes a HSV-2 glycoprotein C, and a fourth mRNA encodes a HSV-2 glycoprotein E, wherein each mRNA has a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, and wherein the uracil nucleotides of the mRNA are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
A herpes simplex virus (HSV) vaccine, comprising
- at least five messenger ribonucleic acid (mRNA) polynucleotides encoding an antigenic HSV polypeptide, wherein a first mRNA polynucleotide encodes a HSV-2 glycoprotein B, a second nmRNA polynucleotide encodes a HSV-2 glycoprotein D antigenic, a third mRNA encodes a HSV-2 glycoprotein C, a fourth mRNA encodes a HSV-2 glycoprotein E, and a fifth mRNA encodes a HSV-2 glycoprotein I, wherein each mRNA has a 5′ terminal cap 7mG(5′)ppp(5′)NlmpNp and a 3′ polyA tail, and wherein the uracil nucleotides of the mRNA are modified to include N1-methyl pseudouridine at the 5-position of the uracil nucleotide.
Dependencies are inferred from the claim text.